Voy­ager nabs $25M cash as No­var­tis runs with two AAV cap­sids for neu­ro gene ther­a­py

Af­ter spend­ing a year look­ing at Voy­ager’s next-gen AAV cap­sids, No­var­tis has picked two of them to be the de­liv­ery vec­tor for its gene ther­a­py pro­grams tar­get­ing two neu­ro­log­ic dis­eases.

The li­cense trig­gers a $25 mil­lion pay­ment — $12.5 mil­lion for each tar­get — and opens up a road to $600 mil­lion in to­tal mile­stones. But it al­so leaves some mon­ey off the ta­ble as No­var­tis, which had the op­tion to li­cense cap­sids against a to­tal of three tar­gets, de­cid­ed not to act on the third.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER